BiDil s Weak Market Performance Could Be Lesson For Other Companies Developing Similar Products | GenomeWeb

Market forces and business decisions that caused NitroMed's race-based cardiac drug BiDil to sell poorly in its first few months could be a lesson for drug makers working on future personalized therapies involving existing drugs.

Disappointing fourth-quarter sales of the heart-failure drug, indicated for black patients because they were found in clinical trials to respond better than non-blacks, caused two of NitroMed's executives to resign last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.